Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2026-03-13 @ 8:40 AM
Study NCT ID:
NCT03731260
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-23
First Post:
2018-10-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D034721', 'term': 'Mastocytosis, Systemic'}], 'ancestors': [{'id': 'D008415', 'term': 'Mastocytosis'}, {'id': 'D009372', 'term': 'Neoplasms, Connective Tissue'}, {'id': 'D018204', 'term': 'Neoplasms, Connective and Soft Tissue'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D000090362', 'term': 'Mast Cell Activation Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000707147', 'term': 'avapritinib'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'In Part 1 of the study, patients will be randomly assigned to 1 of 3 doses of avapritinib or to placebo + BSC. Once the recommended phase 2 dose (RP2D) of avapritinib is identified in Part 1, patients in Part 2 will be randomly assigned to receive avapritinib at the RP2D + BSC or matching placebo + BSC. In Part 3, patients who have completed treatment in Part 1 or Part 2 of the study (including those initially randomized to placebo) may participate in a long-term open-label extension, receiving avapritinib at the RP2D + BSC.'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 251}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2019-04-16', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-09', 'completionDateStruct': {'date': '2027-06-23', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-09-22', 'studyFirstSubmitDate': '2018-10-30', 'studyFirstSubmitQcDate': '2018-11-02', 'lastUpdatePostDateStruct': {'date': '2025-09-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2018-11-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2027-06-23', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Part 1: Recommended Phase 2 dose (RP2D) in patients with ISM', 'timeFrame': '9 months'}, {'measure': 'Part 2: Mean change in ISM Symptom Assessment Form (ISM-SAF) total symptom score (TSS) as compared to placebo', 'timeFrame': '6 months', 'description': '0 - 110 points (higher value represents worse symptom outcomes)'}, {'measure': 'Part 3: Number of Participants with Adverse Events', 'timeFrame': 'Up to 5 years'}], 'secondaryOutcomes': [{'measure': 'Part 2: Proportion of patients with a ≥50% reduction in serum tryptase', 'timeFrame': '6 months'}, {'measure': 'Part 2: Proportion of patients with a ≥50% reduction in peripheral blood V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog aspartate 816 valine (KIT D816V) allele fraction or undetectable for patients with detectable mutation at Baseline', 'timeFrame': '6 months'}, {'measure': 'Part 2: Proportion of patients with ≥50% reduction in ISM-SAF TSS', 'timeFrame': '6 months'}, {'measure': 'Part 2: Proportion of patients with ≥30% reduction in ISM-SAF TSS', 'timeFrame': '6 months'}, {'measure': 'Part 2: Proportion of patients with a ≥50% reduction in bone marrow mast cells or no aggregates for patients with aggregates at Baseline', 'timeFrame': '6 months'}, {'measure': 'Parts 1, 2, and 3: Change in serum tryptase', 'timeFrame': 'Up to 5 years'}, {'measure': 'Parts 1, 2, and 3: Change in KIT D816V allele burden in blood', 'timeFrame': 'Up to 5 years'}, {'measure': 'Parts 1, 2, and 3: Change in bone marrow mast cells', 'timeFrame': 'Up to 5 years'}, {'measure': 'Parts 1, 2, and 3: Change in best supportive care (BSC) concomitant medication usage', 'timeFrame': 'Up to 5 years'}, {'measure': 'Parts 1, 2, and 3: Change from Baseline in ISM-SAF Score', 'timeFrame': 'Up to 5 years'}, {'measure': 'Parts 1, 2, and 3: Change in Mastocytosis Quality of Life Questionnaire (MC-QoL)', 'timeFrame': 'Up to 5 years'}, {'measure': "Parts 1, 2, and 3: Change in Patient's Global Impression of Symptom Severity (PGIS)", 'timeFrame': 'Up to 5 years'}, {'measure': 'Parts 1, 2, and 3: Change in 12-item Short Form Health Survey (SF-12)', 'timeFrame': 'Up to 5 years', 'description': '0 - 100 points (higher value represents better symptom outcomes)'}, {'measure': "Parts 1, 2, and 3: Change in Patients' Global Impression of Change (PGIC)", 'timeFrame': 'Up to 5 years', 'description': '1 - 7 (higher value represents worse symptom outcomes)'}, {'measure': 'Parts 1, 2, and 3: Change in EuroQuol 5 Dimensions 5 Levels (EQ 5D-5L)', 'timeFrame': 'Up to 5 years', 'description': '0 - 100 (higher value represents better symptom outcomes)'}, {'measure': 'Parts 1, 2, and 3: Safety of avapritinib as assessed by number of adverse events', 'timeFrame': 'Up to 5 years', 'description': 'CTCAE version 5.0'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Indolent Systemic Mastocytosis']}, 'referencesModule': {'references': [{'pmid': '41244098', 'type': 'DERIVED', 'citation': 'Worth S, George TI, Shaheen DJ, Roche M, Vachhani P. Chronic Anaphylaxis With Indolent Systemic Mastocytosis: A Case Report. Case Rep Hematol. 2025 Nov 6;2025:9562195. doi: 10.1155/crh/9562195. eCollection 2025.'}, {'pmid': '38320129', 'type': 'DERIVED', 'citation': 'Gotlib J, Castells M, Elberink HO, Siebenhaar F, Hartmann K, Broesby-Olsen S, George TI, Panse J, Alvarez-Twose I, Radia DH, Tashi T, Bulai Livideanu C, Sabato V, Heaney M, Van Daele P, Cerquozzi S, Dybedal I, Reiter A, Pongdee T, Barete S, Ustun C, Schwartz L, Ward BR, Schafhausen P, Vadas P, Bose P, DeAngelo DJ, Rein L, Vachhani P, Triggiani M, Bonadonna P, Rafferty M, Butt NM, Oh ST, Wortmann F, Ungerstedt J, Guilarte M, Taparia M, Kuykendall AT, Arana Yi C, Ogbogu P, Gaudy-Marqueste C, Mattsson M, Shomali W, Giannetti MP, Bidollari I, Lin HM, Sulllivan E, Mar B, Scherber R, Roche M, Akin C, Maurer M. Avapritinib versus Placebo in Indolent Systemic Mastocytosis. NEJM Evid. 2023 Jun;2(6):EVIDoa2200339. doi: 10.1056/EVIDoa2200339. Epub 2023 May 23.'}, {'pmid': '34663404', 'type': 'DERIVED', 'citation': 'Padilla B, Shields AL, Taylor F, Li X, Mcdonald J, Green T, Boral AL, Lin HM, Akin C, Siebenhaar F, Mar B. Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet J Rare Dis. 2021 Oct 18;16(1):434. doi: 10.1186/s13023-021-02037-3.'}]}, 'descriptionModule': {'briefSummary': 'This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The study will be conducted in 3 parts. All patients will receive treatment with avapritinib during Part 3 including those rolling over from the placebo group.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Key Inclusion Criteria:\n\n* 1\\. Patient must have SM, confirmed by Central Pathology Review of BM biopsy, and central review of B- and C-findings by WHO diagnostic criteria.\n* 2\\. Patient must have moderate-to-severe symptoms based on minimum mean total symptom score (TSS) of the ISM Symptom Assessment Form (ISM-SAF) over the 14-day eligibility screening period.\n* 3\\. Patient must have failed to achieve adequate symptom control for 1 or more Baseline symptoms.\n* 4\\. For patients receiving corticosteroids, the dose must be ≤ 20 mg/d prednisone or equivalent, and the dose must be stable for ≥ 14 days.\n* 5\\. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2.\n\nKey Exclusion Criteria:\n\n* 1\\. Patient has been diagnosed with any of the following WHO SM subclassifications: cutaneous mastocytosis only, smoldering SM, SM with associated hematologic neoplasm, aggressive SM, mast cell leukemia, or mast cell sarcoma.\n* 2\\. Patient must not have received prior treatment with avapritinib.\n* 3\\. Patient must not have had any cytoreductive therapy including but not limited to masitinib and midostaurin, or investigational agent for \\< 14 days or 5 half-lives of the drug (whichever is longer), and for cladribine, interferon alpha, pegylated interferon, or antibody therapy \\< 28 days or 5 half-lives of the drug (whichever is longer), before beginning the 14-day ISM-SAF eligibility TSS assessment.\n* 4\\. Patient must not have received radiotherapy or psoralen and ultraviolet A (PUVA) therapy \\< 14 days before beginning the 14-day ISM-SAF eligibility TSS assessment.\n* 5\\. Patient must not have received any hematopoietic growth factor the preceding 14 days before beginning the 14-day ISM-SAF eligibility TSS assessment.\n* 6\\. Patient must not have a QT interval corrected using Fridericia's formula (QTcF) of \\> 480 msec."}, 'identificationModule': {'nctId': 'NCT03731260', 'briefTitle': '(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Blueprint Medicines Corporation'}, 'officialTitle': 'A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy', 'orgStudyIdInfo': {'id': 'BLU-285-2203'}, 'secondaryIdInfos': [{'id': '2018-000588-99', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '(Part 1) Avapritinib Dose 1 + BSC', 'description': 'Avapritinib will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Avapritinib']}, {'type': 'EXPERIMENTAL', 'label': '(Part 1) Avapritinib Dose 2 + BSC', 'description': 'Avapritinib will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Avapritinib']}, {'type': 'EXPERIMENTAL', 'label': '(Part 1) Avapritinib Dose 3 + BSC', 'description': 'Avapritinib will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Avapritinib']}, {'type': 'PLACEBO_COMPARATOR', 'label': '(Part 1) Placebo + BSC', 'description': 'Placebo will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': '(Part 2) Avapritinib RP2D + BSC', 'description': 'Avapritinib will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Avapritinib']}, {'type': 'PLACEBO_COMPARATOR', 'label': '(Part 2) Placebo + BSC', 'description': 'Placebo will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': '(Part 3) Avapritinib RP2D + BSC', 'description': 'Avapritinib will be administered orally in continuous 28-day cycles', 'interventionNames': ['Drug: Avapritinib']}], 'interventions': [{'name': 'Avapritinib', 'type': 'DRUG', 'otherNames': ['BLU-285'], 'description': 'Avapritinib tablet', 'armGroupLabels': ['(Part 1) Avapritinib Dose 1 + BSC', '(Part 1) Avapritinib Dose 2 + BSC', '(Part 1) Avapritinib Dose 3 + BSC', '(Part 2) Avapritinib RP2D + BSC', '(Part 3) Avapritinib RP2D + BSC']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo tablet', 'armGroupLabels': ['(Part 1) Placebo + BSC', '(Part 2) Placebo + BSC']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35294', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'University of Alabama at Birmingham', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '85054', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'Mayo Clinic Hospital', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '94305', 'city': 'Stanford', 'state': 'California', 'country': 'United States', 'facility': 'Stanford Cancer Institute', 'geoPoint': {'lat': 37.42411, 'lon': -122.16608}}, {'zip': '32224', 'city': 'Jacksonville', 'state': 'Florida', 'country': 'United States', 'facility': 'Mayo Clinic Florida', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'H. Lee Moffitt Cancer Center', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Winship Cancer Institute, Emory University', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '66160', 'city': 'Kansas City', 'state': 'Kansas', 'country': 'United States', 'facility': 'University of Kansas Hospital', 'geoPoint': {'lat': 39.11417, 'lon': -94.62746}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Brigham & Women's Hospital", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Dana Farber Cancer Institute', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '48106', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'Michigan Medicine, University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University School of Medicine', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '10032', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Herbert Irving Comprehensive Cancer Center', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27710', 'city': 'Durham', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke University Health System (DUHS)', 'geoPoint': {'lat': 35.99403, 'lon': -78.89862}}, {'zip': '44106', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'University Hospitals Cleveland Medical Center', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas, MD Anderson Cancer Center', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '84112', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'Huntsman Cancer Institute', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '23298', 'city': 'Richmond', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Commonwealth University Medical Center', 'geoPoint': {'lat': 37.55376, 'lon': -77.46026}}, {'zip': '2650', 'city': 'Edegem', 'country': 'Belgium', 'facility': 'University Hospital Antwerp', 'geoPoint': {'lat': 51.15662, 'lon': 4.44504}}, {'zip': 'T2N 4N2', 'city': 'Calgary', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Tom Baker Cancer Centre', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'T6G 2B7', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'University of Alberta Hospital', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'M5B 1W8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': "St. Michael's Hospital", 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'DK-5000', 'city': 'Odense', 'country': 'Denmark', 'facility': 'Odense Universitetshospital, ORCA/Allergicentret, Hudafdeling I og Allergicenter', 'geoPoint': {'lat': 55.39594, 'lon': 10.38831}}, {'zip': '13385', 'city': 'Marseille', 'country': 'France', 'facility': 'Hôpital de la Timone, Service de dermatologie', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'zip': '75013', 'city': 'Paris', 'country': 'France', 'facility': 'Hôpital Pitié-Salpêtrière, Service de Dermatologie', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '31059', 'city': 'Toulouse', 'country': 'France', 'facility': 'CHU Toulouse Larrey, CEREMAST, Service de Dermatologie et Allergologie cutanée', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '52074', 'city': 'Aachen', 'country': 'Germany', 'facility': 'Uniklinik RWTH Aachen', 'geoPoint': {'lat': 50.77664, 'lon': 6.08342}}, {'zip': '10117', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charité Universitätsmedizin Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '20246', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'University Clinic Hamburg Eppendorf, University Cancer Center Hamburg (UCCH)', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '23538', 'city': 'Lübeck', 'country': 'Germany', 'facility': 'Universitätsklinikum Schleswig-Holstein, Hämatologie/Onkologie', 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'zip': '55131', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Universitätsklinik Mainz, Universitäts-Hautklinik, Clinical Research Center', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '68167', 'city': 'Mannheim', 'country': 'Germany', 'facility': 'Universitätsmedizin Mannheim, III. Medizinische Klinik', 'geoPoint': {'lat': 49.4891, 'lon': 8.46694}}, {'zip': '80802', 'city': 'Munich', 'country': 'Germany', 'facility': 'Klinikum rechts der Isar, Technische Universität München', 'geoPoint': {'lat': 48.13743, 'lon': 11.57549}}, {'zip': '40138', 'city': 'Bologna', 'country': 'Italy', 'facility': 'A.O.U di Bologna - IRCCS, Istituto di Ematologia Lorenzo e Ariosto Seragnoli, Ematologia', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '20122', 'city': 'Milan', 'country': 'Italy', 'facility': "Fondazione IRCCS Ca' Granda Ospedale Maggiore Poloclinico, UOC Ematologia", 'geoPoint': {'lat': 45.46427, 'lon': 9.18951}}, {'zip': '84131', 'city': 'Salerno', 'country': 'Italy', 'facility': "A.O. OO.RR. S.Giovanni di Dio e Ruggi d'Aragona, University of Salerno", 'geoPoint': {'lat': 40.67545, 'lon': 14.79328}}, {'zip': '37126', 'city': 'Verona', 'country': 'Italy', 'facility': 'Azienda Ospedaliera Universitaria Integrata di Verona', 'geoPoint': {'lat': 45.43854, 'lon': 10.9938}}, {'zip': '9713 GZ', 'city': 'Groningen', 'country': 'Netherlands', 'facility': 'University Medical Center Groningen (UMCG)', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}, {'zip': '3015 GD', 'city': 'Rotterdam', 'country': 'Netherlands', 'facility': 'Erasmus Medical Center', 'geoPoint': {'lat': 51.9225, 'lon': 4.47917}}, {'zip': '0372', 'city': 'Oslo', 'country': 'Norway', 'facility': 'Oslo Universitetssykehus, Rikshospitalet, Department of Hematology', 'geoPoint': {'lat': 59.91273, 'lon': 10.74609}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitari Vall d'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '45071', 'city': 'Toledo', 'country': 'Spain', 'facility': 'lnstituto de Estudios de Mastocitosis de Castilla la Mancha, Hospital Virgen del Valle - Complejo Hospitalario de Toledo', 'geoPoint': {'lat': 39.8581, 'lon': -4.02263}}, {'zip': '141 86', 'city': 'Stockholm', 'country': 'Sweden', 'facility': 'Karolinska University Hospital, Hematologimottagningen R51', 'geoPoint': {'lat': 59.32938, 'lon': 18.06871}}, {'zip': '751 85', 'city': 'Uppsala', 'country': 'Sweden', 'facility': 'Akademiska sjukhuset, Hematologmottagningen/101A', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'zip': '4031', 'city': 'Basel', 'country': 'Switzerland', 'facility': 'University Hospital Basel', 'geoPoint': {'lat': 47.55839, 'lon': 7.57327}}, {'zip': 'G12 OXL', 'city': 'Glasgow', 'country': 'United Kingdom', 'facility': 'NHS Greater Glasgow and Clyde, Beatson West of Scotland Cancer Centre', 'geoPoint': {'lat': 55.86515, 'lon': -4.25763}}, {'zip': 'SE1 9RT', 'city': 'London', 'country': 'United Kingdom', 'facility': "Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital", 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'zip': 'CH63 4JY', 'city': 'Metropolitan Borough of Wirral', 'country': 'United Kingdom', 'facility': 'Clatterbridge Cancer Centre NHS Foundation Trust', 'geoPoint': {'lat': 53.37616, 'lon': -3.10501}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Blueprint Medicines Corporation', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}